Aardvark Therapeutics, Inc. Common Stock AARD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -58.8%— | —— | —— | —— | —— | |
| Return on assets | -54.7%— | -59.2%— | —— | —— | —— | |
| Return on invested capital | -99.8%— | —— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 8.1×-17.8× | 10.6×-4.4× | 12×— | 14×— | 25.9×— | |
| Quick ratio | 8.1×-17.8× | 10.6×-4.4× | 12×— | 14×— | 25.9×— | |
| Cash ratio | 5.4×+0.9× | 4.5×-8.1× | 3.7×— | 2.5×— | 4.4×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×— | 0×— | 0×— | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $3.99-65.1% | $5.43+140% | $5.64+149% | $6.31+159% | $11.42+223% | |
| Valuation | ||||||
| Market capitalization | $124.35M-58.6% | $285.77M— | $288.3M— | $341.81M— | —— | |
| Enterprise value | $62.25M-77.4% | $239.16M— | $249.56M— | $316.45M— | —— | |
| Price / book | 1.4×-0.8× | 2.7×— | 2.4×— | 2.5×— | —— | |
| Earnings yield | -56.2%-44.0pp | -20.2%— | -16.9%— | -10.7%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Aardvark Therapeutics, Inc. Common Stock's ratios come from?
- Every ratio is computed from Aardvark Therapeutics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.